226.02
0.87 (0.39%)
| Previous Close | 225.15 |
| Open | 225.34 |
| Volume | 344,845 |
| Avg. Volume (3M) | 1,567,536 |
| Market Cap | 38,491,205,632 |
| Price / Earnings (TTM) | 31.05 |
| Price / Earnings (Forward) | 15.46 |
| Price / Sales | 2.24 |
| Price / Book | 5.60 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | 7.88% |
| Operating Margin (TTM) | 13.39% |
| Diluted EPS (TTM) | 6.89 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Quarterly Earnings Growth (YOY) | -26.70% |
| Total Debt/Equity (MRQ) | 272.12% |
| Current Ratio (MRQ) | 0.840 |
| Operating Cash Flow (TTM) | 2.62 B |
| Levered Free Cash Flow (TTM) | 2.45 B |
| Return on Assets (TTM) | 5.16% |
| Return on Equity (TTM) | 19.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | IQVIA Holdings, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -1.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.80 |
|
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 1.05% |
| % Held by Institutions | 98.21% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 290.00 (Truist Securities, 28.31%) | Buy |
| Median | 242.50 (7.29%) | |
| Low | 200.00 (Citigroup, -11.51%) | Hold |
| Average | 241.00 (6.63%) | |
| Total | 7 Buy, 3 Hold | |
| Avg. Price @ Call | 201.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 06 Feb 2026 | 210.00 (-7.09%) | Hold | 180.96 |
| Citigroup | 06 Feb 2026 | 200.00 (-11.51%) | Hold | 180.96 |
| JP Morgan | 06 Feb 2026 | 225.00 (-0.45%) | Buy | 180.96 |
| Jefferies | 06 Feb 2026 | 255.00 (12.82%) | Buy | 180.96 |
| Stifel | 06 Feb 2026 | 220.00 (-2.66%) | Buy | 180.96 |
| UBS | 06 Feb 2026 | 240.00 (6.19%) | Buy | 180.96 |
| 08 Jan 2026 | 280.00 (23.88%) | Buy | 243.19 | |
| TD Cowen | 22 Jan 2026 | 245.00 (8.40%) | Hold | 239.05 |
| Truist Securities | 08 Jan 2026 | 290.00 (28.31%) | Buy | 243.19 |
| Morgan Stanley | 02 Dec 2025 | 265.00 (17.25%) | Buy | 225.63 |
| BMO Capital | 13 Nov 2025 | 260.00 (15.03%) | Buy | 223.55 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FEDOCK MICHAEL J. | - | 239.76 | -381 | -91,349 |
| Aggregate Net Quantity | -381 | |||
| Aggregate Net Value ($) | -91,349 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 239.76 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FEDOCK MICHAEL J. | Officer | 28 Jan 2026 | Disposed (-) | 381 | 239.76 | 91,349 |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance |
| 29 Jan 2026 | Announcement | IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration |
| 22 Jan 2026 | Announcement | IQVIA Named to the Fortune® World’s Most Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year |
| 20 Jan 2026 | Announcement | IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026 |
| 02 Dec 2025 | Announcement | IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |